Healthcare · Biotechnology
Price
$8.67
Market Cap
$627.5M
Employees
202
Beta
2.53
Avg Volume
1,617,467
CEO
Gregory A. Demopulos
Business Description
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
Business History
Price Overview
Last updated: Jun 27, 2026 8:02am (just now)$8.67
-2.05 (-19.12%)
Day Range
$7.39 – $8.89
52-Week Range
$2.95 – $17.65
50-Day MA
$12.06
200-Day MA
$10.26
Volume
10,912,878.00
Analyst Price Targets
Low
$40.00
Consensus
$40.00
High
$40.00
(4 analysts)
Share Structure
Outstanding
72,375,355.00
Float
69,786,489.00
Free Float
96.4%
High free float
— 96.4% of shares trade freely, ~3.6% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
7.24
Stock Price: $8.67
EPS (Diluted): -0.05
EPS (Diluted): -0.05
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-9.00
Stock Price: $8.67
Total Equity: -$121.23M
Shares: 63,510,201
Total Equity: -$121.23M
Shares: 63,510,201
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
10.08
Market Cap: $627.49M
Total Debt: $225.60M
Cash: $9.66M
EBITDA: -$1.83M
Total Debt: $225.60M
Cash: $9.66M
EBITDA: -$1.83M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$1.3B
Market Cap: $627.49M
Total Debt: $225.60M
Cash: $9.66M
Total Debt: $225.60M
Cash: $9.66M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $8.67
Revenue: $0.00
Shares: 63,510,201
Revenue: $0.00
Shares: 63,510,201
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$122.80M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$3.35M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-54.4%
Net Income: -$3.35M
Total Equity: -$121.23M
Total Equity: -$121.23M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-40.6%
Operating Income: -$122.80M
Tax Rate: -72.0%
Equity: -$121.23M
Total Debt: $225.60M
Cash: $9.66M
Tax Rate: -72.0%
Equity: -$121.23M
Total Debt: $225.60M
Cash: $9.66M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.76
Current Assets: $215.67M
Current Liabilities: $78.06M
Current Liabilities: $78.06M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-1.86
Short-Term Debt: $17.06M
Long-Term Debt: $208.54M
Total Debt: $225.60M
Total Equity: -$121.23M
Long-Term Debt: $208.54M
Total Debt: $225.60M
Total Equity: -$121.23M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 63,510,201
Shares: 63,510,201
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-1.91
Total Equity: -$121.23M
Shares: 63,510,201
Shares: 63,510,201
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.83
Operating CF: -$116.09M
CapEx: -$65,000
Shares: 63,510,201
CapEx: -$65,000
Shares: 63,510,201
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $8.67
Stock Price: $8.67
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$3.35M
Net Income: -$3.35M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares OMER against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 27, 2026 8:02am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $1.4M | $0 | $0 | $0 | $0 |
| Gross Profit | -$1.4M | $0 | $0 | $0 | $0 |
| Operating Expenses | $172.2M | $163.4M | $164.5M | $169.3M | $122.8M |
| Operating Income | -$173.6M | -$163.4M | -$164.5M | -$169.3M | -$122.8M |
| Net Income | -$111.4M | $47.4M | -$117.8M | -$156.8M | -$3.4M |
| EBITDA | -$170.5M | -$158.4M | -$143.2M | -$157.0M | -$1.8M |
| EPS | $3.12 | $0.46 | $-1.88 | $-2.70 | $-0.05 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 27, 2026 8:02am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $100.8M | $11.0M | $7.1M | $3.4M | $9.7M |
| Total Current Assets | $248.0M | $443.2M | $217.9M | $134.1M | $215.7M |
| Total Assets | $419.3M | $591.0M | $378.3M | $277.1M | $325.6M |
| Current Liabilities | $51.8M | $136.4M | $53.3M | $79.5M | $78.1M |
| Long-Term Debt | $313.5M | $220.9M | $329.7M | $166.6M | $208.5M |
| Total Liabilities | $395.5M | $505.3M | $403.3M | $459.7M | $446.9M |
| Total Equity | $23.8M | $85.7M | -$25.0M | -$182.6M | -$121.2M |
| Retained Earnings | -$683.1M | -$635.7M | -$753.5M | -$910.3M | -$913.7M |
Cash Flow (Annual)
Last updated: Jun 27, 2026 8:02am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$109.7M | -$86.5M | $74.7M | -$148.8M | -$116.1M |
| Capital Expenditure | $-277,000 | $-113,000 | $-426,000 | $-165,000 | $-65,000 |
| Free Cash Flow | -$110.0M | -$86.6M | $74.3M | -$149.0M | -$116.2M |
| Acquisitions (net) | $126.0M | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | -$4.7M | -$11.9M | $0 |
| Net Change in Cash | $90.3M | -$89.8M | -$3.9M | -$3.7M | $6.3M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 8:02am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$143.3M $131.9M – $160.2M
|
$266.3M $245.1M – $297.7M
|
$403.9M $371.8M – $451.6M
|
$501.9M $462.0M – $561.1M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$12.8M -$14.4M – -$11.2M
|
$63.5M $58.4M – $68.6M
|
$119.4M $107.0M – $137.7M
|
$179.1M $160.6M – $206.6M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 27, 2026 8:02am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | +100.0% | — | — | — |
| Operating Income Growth | +5.9% | -0.7% | -2.9% | +27.5% |
| Net Income Growth | +142.6% | -348.5% | -33.1% | +97.9% |
| EBITDA Growth | +7.1% | +9.6% | -9.7% | +98.8% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-18 | Shah Rajiv | A-Award | 15,000.00 | $10.28 | $154,200 |
| 2026-06-18 | Perkinson Diana T. | A-Award | 15,000.00 | $10.28 | $154,200 |
| 2026-06-18 | Hood Leroy E. MD PhD | A-Award | 15,000.00 | $10.28 | $154,200 |
| 2026-06-18 | HANISH ARNOLD C | A-Award | 15,000.00 | $10.28 | $154,200 |
| 2026-06-18 | Demopulos Peter A MD | A-Award | 15,000.00 | $10.28 | $154,200 |
| 2026-06-18 | Cable Thomas J. | A-Award | 15,000.00 | $10.28 | $154,200 |
| 2026-06-18 | Bumol Thomas F. | A-Award | 15,000.00 | $10.28 | $154,200 |
| 2026-05-22 | Cable Thomas J. | M-Exempt | 7,500.00 | $10.84 | $81,300 |
| 2026-05-22 | Cable Thomas J. | S-Sale | 7,500.00 | $11.61 | $87,039 |
| 2026-05-22 | Cable Thomas J. | M-Exempt | 7,500.00 | $10.84 | $81,300 |
| 2026-02-18 | Demopulos Gregory A MD | M-Exempt | 400,000.00 | $10.27 | $4.1M |
| 2026-02-18 | Demopulos Gregory A MD | F-InKind | 357,678.00 | $11.93 | $4.3M |
| 2026-02-18 | Demopulos Gregory A MD | M-Exempt | 400,000.00 | $10.27 | $4.1M |
| 2026-01-13 | Borges David J. | M-Exempt | 30,000.00 | $3.06 | $91,800 |
| 2026-01-13 | Borges David J. | M-Exempt | 30,000.00 | $3.06 | $91,800 |
| 2026-01-12 | Borges David J. | S-Sale | 30,000.00 | $12.72 | $381,600 |
| 2026-01-13 | Borges David J. | S-Sale | 30,000.00 | $12.31 | $369,315 |
| 2025-10-13 | Demopulos Gregory A MD | G-Gift | 600,000.00 | $0.00 | $0 |
| 2025-10-13 | Demopulos Gregory A MD | G-Gift | 300,000.00 | $0.00 | $0 |
| 2025-06-30 | Demopulos Gregory A MD | A-Award | 865,000.00 | $3.20 | $2.8M |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for OMER — it's generated by the pipeline (
market-narrative step).
No community reviews yet for OMER.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30